SCHEMBL1966583

SCHEMBL1966583

CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC(F)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
GLA P06280 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DPP4 P27487 1/20 0.39
THRB P10828 2/20 0.39
GPR119 Q8TDV5 2/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1622326 0.87 MAPT (0.43) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL19073664 0.82 ALDH1A1 (0.39) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL19073726 0.80 MEN1 (0.45) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL652243 0.80 MEN1 (0.45) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL31257394 0.79 TP53 (0.44) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL183757 0.79 MEN1 (0.44) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL20015491 0.79 MEN1 (0.44) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL29450286 0.78 MAPT (0.46) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL183637 0.78 MAPT (0.46) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL4167125 0.77 HPGD (0.47) MAPTALDH1A1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 US disclosed
US-20260001887-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2026-01-01 US disclosed
US-8987251-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-24 US disclosed
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-8575145-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-11-05 US disclosed
EP-2334677-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-10-09 EP disclosed
EP-2334677-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-06-22 EP disclosed
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
WO-2010022076-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK6 MAPT 4239/4885ALDH1A1 2275/4885MEN1 3823/4885
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 MAPT 3648/4885ALDH1A1 2440/4885MEN1 3598/4885
US-20260001887-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK2 MAPT 4335/4885ALDH1A1 2858/4885MEN1 3872/4885
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 MAPT 3834/4885ALDH1A1 1820/4885MEN1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.